Filing Flows › Vir Biotechnology (VIR) › Q4 2025
Vir Biotechnology (VIR) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 23, 2026
Vir Biotechnology (VIR) reported revenue of $64.1M for the fourth quarter 2025 (Q4 2025), +418% from a year earlier and up 267-fold from the quarter before. Operating margin was -74.8%, net loss $42.9M (67.0% of revenue).
Vir Biotechnology, Q4 2025: revenue $64.1M (+418% year over year), operating margin -74.8%, net loss $42.9M, operating cash flow −$25.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $64.1M | 267× | +418% |
| Operating profit | −$47.9M | — | — |
| Net earnings | −$42.9M | — | — |
| Operating cash flow | −$25.9M | — | — |
What changed
Revenue was $64.1M in Q4 2025, up 418% year over year and up 26596% from the previous quarter.
Operating costs exceeded revenue by $47.9M, an operating margin of -74.8%. Total costs fell 14% while revenue rose 418%. The quarter ended with a net loss of $42.9M, narrower than the previous quarter's $163.1M loss.
Operating cash flow was −$25.9M. Non-cash charges added back $2.9M of depreciation and amortization and $11.2M of share-based compensation. Working capital and other items added $2.9M. Capital expenditures of $348K exceeded it, leaving free cash flow of −$26.2M.
Questions
What was Vir Biotechnology's revenue in the fourth quarter 2025?
Vir Biotechnology (VIR) reported revenue of $64.1M for the fourth quarter 2025 (Q4 2025), +418% from a year earlier and up 267-fold from the quarter before.
Was Vir Biotechnology profitable in the fourth quarter 2025?
Operating loss was $47.9M (-74.8% of revenue) and net loss $42.9M.
Source: Vir Biotechnology 10-K on SEC EDGAR.